EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Data of Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib: A Single-Center Experience from Eastern India

Anish Dasgupta, Deepak Dabkara, Arnab Bhattacharjee, Somnath Roy, Soumendranath Ray, Kapila Manikantan, Pattatheyil Arun

Indian Journal of Medical and Paediatric Oncology · 01.02.2026 · 47 (01) · A01-A58

DOI: 10.1055/s-0046-1818529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.02.2026. Verfasst von Anish Dasgupta und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims and Objectives: Treatment of differentiated thyroid cancer consists of surgery with or without radioiodine (RAI) therapy. For patients who develop radioiodine refractory disease, without any targetable mutation, the use of oral tyrosine kinase inhibitors (TKI) like Lenvatinib and Sorafenib is standard practice. The primary aim of this study is to assess the response, progression free survival (PFS) of patients of Radioiodine Refractory Thyroid Cancer on Lenvatinib; overall survival (OS) and toxicity were secondary endpoints. Materials and Methods: This was a retrospective study from Tata Medical Center Kolkata, India, which included patients with RAI refractory differentiated thyroid cancer between 2012 and 2024. Data were captured from hospital electronic medical records till June 2024. Standard or lower doses of lenvatinib was offered as first-line therapy after RAI therapy completion.

Results

Consecutive 32 eligible patients (male:female:15:17) were analyzed, with median age at diagnosis 55 years (range 12–70). The mean cumulative dose of RAI was 333 mCi (interquartile range: 161). The median starting dose of lenvatinib was 16 mg (range: 8–24). With a median follow-up of 17 months, disease control rate (CR + PR + SD) was 90%. 3 patients developed progression at first response assessment. Dose modification of lenvatinib was done in 26 patients as per guidelines, with a minimum dose level of 4 mg. Cabozantinib was offered as second-line therapy to 10 patients. Median PFS was 23 months (95% CI: 15–30) and median OS was 137 months (95% CI: 93–180). The most common adverse effects (CTCAE version 5) were Grade 2 skin rash (12), HFS-hand-foot syndrome (5); whereas Grade 3 were HFS (7) and proteinuria (2).

Conclusion

This study shows that even lower doses of lenvatinib were equally efficacious in terms of response and outcome in RAI refractory thyroid cancer as compared to standard dose reported in landmark trials and can be offered among patients where full dose cannot be attempted. Publication History Article published online: 20 February 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Zitieren

APA

Dasgupta, A., Dabkara, D., Bhattacharjee, A., Roy, S., Ray, S., Manikantan, K., & Arun, P. (2026). Real-World Data of Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib: A Single-Center Experience from Eastern India. Indian Journal of Medical and Paediatric Oncology, 47(01), A01-A58. https://doi.org/10.1055/s-0046-1818529

Vancouver

Dasgupta A, Dabkara D, Bhattacharjee A, Roy S, Ray S, Manikantan K, et al. Real-World Data of Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib: A Single-Center Experience from Eastern India. Indian Journal of Medical and Paediatric Oncology. 2026;47(01):A01-A58. doi:10.1055/s-0046-1818529

BibTeX
@article{Dasgupta2026,
  author = {Dasgupta, Anish and Dabkara, Deepak and Bhattacharjee, Arnab and Roy, Somnath and Ray, Soumendranath and Manikantan, Kapila and Arun, Pattatheyil},
  title = {Real-World Data of Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib: A Single-Center Experience from Eastern India},
  journal = {Indian Journal of Medical and Paediatric Oncology},
  year = {2026},
  volume = {47},
  number = {01},
  pages = {A01--A58},
  doi = {10.1055/s-0046-1818529}
}
Kostenlos starten →